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Abstract
Pyrethroid insecticides are suspected endocrine-disrupting chemicals. 
Deltamethrin has been reported to antagonize thyroid hormone receptor activity in a 
reporter assay. We hypothesized that deltamethrin alters thyroid function. Male and 
female rats were administered daily oral gavages with 0, 0.3, 1, or 3 mg/kg/day delta-
methrin on postnatal days 23–53 and 22–42, respectively. Results showed that delta-
methrin decreased the relative thyroid weight in 0.3 and 1 mg/kg/day in female but 
not in male rats. Although the histology and several parameters of thyroid were not 
affected, the decreased relative weight exhibited underlying meaning. Deltamethrin 
delayed the age of vaginal opening (VO) and increased body weight upon VO in 
3 mg/kg/day. Deltamethrin failed to delay the age of preputial separation in male 
rats. In the respective of serum hormone concentration, deltamethrin increased 
17β-estradiol (E2) with dose-dependent manner in female rats. The novel finding 
is that deltamethrin decreased thyroxine (T4), triiodothyronine (T3), and thyroid-
stimulating hormone (TSH) in the female rats. In contrast, deltamethrin increased 
T3 and TSH but not in T4 in male rats. We inferred that deltamethrin disrupts thyroid 
hormone and might be related to estrogen receptor agonist. The future work is to 
investigate if deltamethrin disrupts the hypothalamus-pituitary-thyroid axis.
Keywords: thyroid hormone, deltamethrin, vaginal opening, preputial separation, 
pubertal rats
1. Introduction
Environmental endocrine disruptors (EDs) have been the subject of public atten-
tion since the publication of Rachel Carson’s Silent Spring [1]. Problems associated 
with EDs have been studied, and EDs have been suggested not only to produce repro-
ductive and developmental toxicity in experimental animals but also to increase the 
incidence of cancers, such as those of the mammary gland, testis, and prostate, and 
to decrease sperm numbers and induce developmental abnormalities in wildlife and 
humans by disrupting the endocrine system [2, 3]. Faced with an emerging health 
threat, the U.S. Environmental Protection Agency (U.S. EPA) identified research 
requirements for future risk assessments regarding endocrine-disrupting chemicals 
(EDCs) [4, 5].
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The Endocrine Disruptor Screening and Testing Advisory Committee of the 
U.S. EPA has recommended a screening strategy to investigate endocrine-disrupting 
compounds that are agonists/antagonists to estrogen/androgen receptors, steroid 
biosynthesis inhibitors, or altering thyroid hormone function [6]. Pubertal female 
and male rat models were designed to investigate alterations of female and male 
pubertal development, thyroid function, and hypothalamic-pituitary-thyroid 
(HPT) function, respectively. The intact 22- or 23-day-old weanling female and male 
rats were exposed to the test substance for 20 or 30 days during the pubertal devel-
opment period [7, 8].
HPT function has been used extensively to review vertebrate species, teleosts, 
amphibians [9, 10], and mammals [11, 12]. In normal thyroid gland functioning, 
thyrotropin-releasing hormone (TRH) is released from the hypothalamus. TRH trav-
els to the anterior pituitary and triggers the release of thyroid-stimulating hormone 
(TSH), or thyrotropin, from the thyrotrophic cells in the pars distalis of the adeno-
hypophysis. An increase in TSH production leads to an increase in thyroid hormone 
(TH) synthesis. TSH binds to receptors on the membrane of the thyroid follicle cells, 
thereby stimulating the biosynthesis of the iodine-containing THs, thyroxine (T4), 
and triiodothyronine (T3). T4 is the principle TH secreted from the thyroid gland; 
however, it is quickly metabolized into T3, the more potent TH. T3 and T4 can exert 
negative feedback control over anterior pituitary to inhibit further release of TSH 
[13, 14].
Synthetic pyrethroids are a class of insecticides listed by the U.S. EPA as 
potential EDCs [15]. Pyrethroids are widely used in agriculture and public health. 
Deltamethrin ((S)-α-cyano-3-phenoxybenzyl-(1R)-cis-(2, 2-dibromovinyl)-2, 
2-dimethylcyclo-propane carboxylate) is the membrane of the type-II synthetic 
pyrethroid pesticide, which is commonly used worldwide. The major site of action 
of deltamethrin seems to be the voltage-dependent sodium channel. However, most 
recent studies on deltamethrin-related toxicity have focused on testicular and epi-
didymal toxicity with decreasing weights, damage to the diameter of seminiferous 
tubules [16], abnormal morphology of spermatozoa, and sloughing and vacuolization 
[17–23] in male rats and mice. The second related form of toxicity caused by delta-
methrin is neurotoxicity. Previous studies have shown that deltamethrin-induced 
neurobehavioral toxicity [24] in parent rats and increased cytochrome P450 expres-
sion are involved in the neuroendocrine functions in their offspring [25, 26].  
The most significant effects of neurotoxicity in rats include decreased neuronal 
sodium channel expression [27, 28], motor coordination deficit [29], decreased 
motor activity and activity of the striatal dopaminergic system [30], cell death in 
the hippocampus and deficits in hippocampal precursor proliferation [31], and 
decreased ambulatory motor activity [32]. A previous study showed that deltame-
thrin decreases messenger RNA expression of specific genes that may potentially 
disrupt normal adipogenesis and lipid and glucose metabolism [33]. Recently, an 
epidemiologic finding showed that deltamethrin might be a risk factor for attention 
deficit hyperactivity disorder [34].
Although deltamethrin induces male reproductive toxicity and neurotoxicity, 
it remains unclear whether deltamethrin causes endocrine disruption. According 
to structural similarities and in vitro research, pyrethroid insecticides (including 
deltamethrin and its metabolite, 3-phenoxybenzoic acid) can affect the TH system 
by interfering with the nuclear TH receptors [35]. Furthermore, daily administration 
of 6.25–25 mg/kg/day deltamethrin for 15 days was shown to decrease the serum and 
cerebral cortex levels of T4 and T3 in the mitochondria of the cortex and hippocampi of 
rats [36]. However, in another study, an oral gavage with a single 15 mg/kg dose of del-
tamethrin or 3 mg/kg/day of deltamethrin for 30 days failed to change TH levels [37]. 
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However, the exposure time for the high dosage (15 mg/kg) may have been too short, 
and when a lower dosage (3 mg/kg/day for 30 days) was administered, exposure may 
have been too low to disturb TH levels. Little is known about the molecular and cel-
lular mechanisms that mediate TH action in the developing brain or developmental 
events [38].
The Toxicology in the 21st Century (Tox21) program is a federal collaboration 
between U.S. government agencies. The program utilizes high-throughput screen-
ing (HTS) to quickly and efficiently test chemicals for activity across a battery of 
assays targeting cellular processes such as the agonistic and antagonistic activities 
of androgen receptors, estrogen receptors, and thyroid receptors (TRs) [39]. The 
Tox21 databank showed that deltamethrin exhibited TR antagonistic activity. 
Furthermore, Du et al. [35] showed that deltamethrin exhibited TR and androgen 
receptor antagonistic activities in reporter assays. Few studies have investigated 
endocrine-disrupting activity in nuclear receptors (especially in androgen recep-
tors, estrogen receptors, and TRs) or deltamethrin-induced dysfunction of the 
hypothalamus-pituitary-gonad (HPG) and HPT axes; many studies, however, have 
investigated male reproductive toxicity and neurotoxicity. Based on previous reports 
regarding testicular and epididymal toxicity, neurotoxicity, and TR receptor antago-
nists from the Tox21 databank, we hypothesized that deltamethrin might disturb 
thyroid-related function. We studied pubertal development and thyroid function 
in male and female Wistar rats to investigate the possible effects of deltamethrin on 
endocrine activity [35].
2. Materials and methods
2.1 Chemicals
The following materials were obtained: testosterone propionate 
(TP, purity ≥ 97%), flutamide (purity ≥ 97%), corn oil (0.9 g/ml), 
17α-ethinylestradiol (purity ≥ 98%) (Sigma-Aldrich Co., St. Louis, MO, USA), 
and deltamethrin (purity ≥ 97%; Sinon Co., Taichung, Taiwan, ROC).
2.2 Animals
The animal use protocol was reviewed and approved by the Institutional 
Animal Care and Use Committee of the Taiwan Agricultural Chemicals and Toxic 
Substances Research Institute. Five-week-old male and female Wistar rats were 
purchased from BioLASCO (Taipei, Taiwan, ROC). The rats were acclimated to 
the laboratory environment and reared under a controlled temperature (21 ± 2°C), 
humidity (40–70%), frequency of ventilation (at least 10/h), and alternating 12 h 
cycles of light and darkness. The rats were administered a pellet rodent diet and 
water ad libitum until they were sacrificed. At 12 weeks of age, the 18 male and 
18 female rats within each treatment group were allowed to mate over a 14-day 
period. Gestation day (GD) 0 was defined as the day that sperm was observed 
in the vagina of the female following mating. Dams were allowed to deliver 
their pups naturally. Any litters with fewer than eight pups (i.e., including both 
male and female pups) or not delivered by GD 23 were excluded from the study. 
Sufficient litter numbers needed to be available to assure that 7–10 female and 10 
male pups were available per treatment group and to avoid the need for placing lit-
termates in the same experimental groups. A population of female and male pups 
that was as homogeneous as possible was selected by eliminating an equal number 
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of pups from the heavy and the light ends of the distribution, leaving the number 
of animals required in the middle of the distribution. The pups were assigned to 
treatment groups such that the mean body weights and variances for all groups 
were similar. Animal allocation to treatment groups was conducted on the basis 
of body weight randomization to ensure unbiased weight distribution across all 
groups.
2.3 Treatment
Each male offspring was weighed and clinically observed, and measurements were 
recorded daily prior to treatment. Treatments (control; TP 0.4 mg/kg/day; flutamide 
3 mg/kg/day; deltamethrin 0.3, 1, or 3 mg/kg/day) were administered daily by oral 
gavage on postnatal day (PND) 23–53. Beginning on PND 30, males were examined 
daily for preputial separation (PPS). Males were dosed and sacrificed from 2 h after 
dosing on PND 53. Each female offspring was weighed and clinically observed, 
and its measurements were recorded daily prior to treatment. Treatments (control; 
17α-ethinyl estradiol [EE] 5 mg/kg/day; deltamethrin 0.3, 1, or 3 mg/kg/day) were 
administered daily by oral gavage from PND 22 to 42. Females were examined daily 
for vaginal opening (VO). Females were dosed and sacrificed from 2 hours after 
dosing on PND 42.
2.4 Clinical signs and body weights
Throughout the study period, each female and male animal was observed at least 
once daily for clinical signs of toxicity related to chemical treatment. On working 
days, all cages were checked in the mornings and afternoons for dead or moribund 
animals. The body weight of each rat was recorded to the nearest 0.1 g daily prior to 
treatment.
2.5 Measurement of organ weights
Twenty-four hours after the final treatment, each rat was treated with the 
control (females and males); EE 5 mg/kg/day (females); TP 0.4 mg/kg/day (males); 
flutamide 3 mg/kg/day (males); and deltamethrin 0.3 or 1 mg/kg/day (females and 
males) and anesthetized with Zoletil 3 mg/kg/day (females and males) in the same 
sequence that the test substance was administered. Uteri and ovaries were dissected 
and carefully trimmed of fat to avoid loss of luminal content. The body of each 
uterus was cut just above its junction with the cervix and at the junction of the uter-
ine horns with the ovaries. Each uterus was weighed with and without the luminal 
content. Thyroids, livers, kidneys, pituitary glands, adrenal glands, ovaries, seminal 
vesicles, and coagulating glands with and without fluid, prostates, levator ani plus 
bulbocavernosus muscles (LABC), epididymides, testes, and penes were carefully 
dissected and weighed.
2.6 VO
Each female animal was examined daily for VO from PND 21. On the day that 
VO was first detected, the age and body weight were recorded. Vaginal lavage was 
collected daily from the day following VO until the end of the study by repeated 
pipetting of 0.9% saline into the vagina. The lavage fluid was applied to a clean 
glass slide, and the smear was viewed immediately under low magnification (×100) 
with a microscope. Cytology was evaluated and the stage of the estrous cycle was 
determined using the method described by Everett [40]. The appearance of a small 
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“pinhole,” vaginal thread, and complete VO were all recorded on the days they 
were observed. The day of complete VO was the endpoint in the analysis for the age 
upon VO; a pinhole or thread did not represent complete VO, even though it had to 
be recorded when observed. However, if any animal within any treatment group 
showed incomplete opening (such as persistent threads or a pinhole) for more than 
3 days, a separate analysis was conducted using the ages at which an incomplete 
opening was first observed. Even if VO otherwise appeared complete, documenta-
tion of a vaginal thread was crucial. It was also critical that the “initiation” of VO be 
recorded and preferred that VO observations be taken daily after dosing. Whether 
collected before or after dosing, VO observations had to be collected at approxi-
mately the same time each day.
2.7 Estrous cyclicity
From the day of VO up to and including the day of necropsy, daily vaginal 
smears were obtained and evaluated under a low-power light microscope for the 
presence of leukocytes, nucleated epithelial cells, or cornified epithelial cells. 
The vaginal smears were classified as diestrus (predominance of leukocytes 
mixed with some cornified epithelial cells), proestrus (predominance of clumps 
of round, nucleated epithelial cells), or estrus (predominance of cornified 
epithelial cells), and the stages were recorded daily. Metestrus was classified as 
an early part of diestrus rather than a late part of estrus. Age upon first vaginal 
estrus was noted, and it was preferred (although not critical) that estrous cycle 
observations be made after daily dosing. Whether collected before or after 
dosing, estrous cycle observations had to be collected at approximately the same 
time each day.
At the end of the study, the overall pattern of each female was characterized as 
regularly cycling (having recurring 4- to 5-day cycles), irregularly cycling (having 
cycles with periods of diestrus longer than 3 days or periods of cornification longer 
than 2 days), or not cycling (having prolonged periods of either vaginal cornification 
or leukocytic smears). In cases where there were too few days between VO and the 
end of the study for more than one cycle to be observed, classification was based on 
the available data with the default assumption that the animals cycled regularly if the 
partial data fit the definition and irregularly if the study ended without being able to 
distinguish between irregular cycling and not cycling.
2.8 PPS
PPS, the separation of the foreskin of the penis from the glans, is an early 
reliable marker of the pubertal progression that normally occurs between 40 and 
50 days of age, with an average of 43 days, depending on the rat species [41]. In the 
present study, PPS was monitored from PND 22 to 53. All males were monitored at 
approximately the same time each day. A partial separation with a thread of carti-
lage remaining was recorded as partial, but only the day of complete separation was 
used in the data analysis. The appearance of partial and complete PPS or a persis-
tent thread of tissue between the glans and prepuce were all recorded on the days 
they were observed. The day of complete PPS was the endpoint used in the analysis 
for the age upon PPS. However, if any animal in any treatment group showed 
incomplete separation (including persistent threads) for more than 3 days, a 
separate analysis was conducted using the ages at which partial separation was first 
observed. Even if PPS otherwise appeared complete, documentation of a thread 
was crucial. It was also critical that “initiation” of PPS be recorded and preferred 
that PPS observations be taken after daily dosing. Whether collected before or after 
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dosing, the PPS observations had to be collected at approximately the same time 
each day.
2.9 Hematochemistry
Blood samples treated with control (females and males), EE 5 mg/kg/day 
(females), TP 0.4 mg/kg/day (males), flutamide 3 mg/kg/day (males), and deltame-
thrin 0.3, 1, and 3 mg/kg/day (female and male) were collected and coagulated for 
30 min in an SST II tube (#367953, BD Co., Plymouth, UK). The blood samples were 
put on ice bath prior to centrifugation. After coagulation, the blood was centrifuged 
at 3000 × g for 15 min. The serum was transferred into siliconized microcentrifuge 
tubes and stored at −80°C until used. Serum creatinine and blood urea nitrogen 
levels were detected with an automated clinical chemistry analyzer (DRI-CHEM 
4000i, Fujifilm Co., Tokyo, Japan).
2.10 Hormonal measurements
Luteinizing hormone (LH); follicle-stimulating hormone (FSH); T4, T3, and 
TSH levels in serum treated with control (females and males); EE 5 mg/kg/day 
(females); TP 0.4 mg/kg/day (males); flutamide 3 mg/kg/day; and deltamethrin 
0.3, 1, and 3 mg/kg/day (females and males) were determined using a magnetic 
bead panel (#RPTMAG-86K, #PTHYMAG-30K, Millipore Co., St. Charles, MI, 
USA).
Testosterone (T) and estradiol (E2) levels in serum treated with control 
(female and male), 5 mg/kg/day 17α-ethinyl estradiol (EE 5) (female), 0.4 mg/
kg/day testosterone propionate (TP 0.4) (male), 3 mg/kg/day flutamide, 0.3, 1, 
and 3 mg/kg/day deltamethrin (female and male) were assayed using EIA kit 
(#582701, #582251, Cayman Co.). Luteinizing hormone (LH), follicle-stimulating 
hormone (FSH), total tetraiodothyronine (T4), triiodothyronine (T3), and 
thyroid-stimulating hormone (TSH) levels in serum treated with control (female 
and male), 5 mg/kg/day 17α-ethinyl estradiol (EE 5) (female), 0.4 mg/kg/day 
testosterone propionate (TP 0.4) (male), 3 mg/kg/day flutamide, 0.3, 1, and 
3 mg/kg/day deltamethrin (female and male) were determined using magnetic 
bead panel (#RPTMAG-86K, #PTHYMAG-30K, Millipore Co.). A cytochrome 
P450 19A1 ELISA kit (CSB-EL006394RA, Cusabio Co.) was used for determined 
aromatase level in serum treated with control (female and male), 5 mg/kg/day 
17α-ethinyl estradiol (EE 5) (female), 0.4 mg/kg/day testosterone propionate (TP 
0.4) (male), 3 mg/kg/day flutamide, 0.3, 1, and 3 mg/kg/day deltamethrin (female 
and male).
2.11 Histology
The tissues of the thyroid glands (females and males), pituitary glands (females 
and males); uteri, ovaries, testes, epididymides, and prostates of rats treated with 
control (females and males); EE 5 mg/kg/day (females); TP 0.4 mg/kg/day (males); 
flutamide 3 mg/kg/day; and deltamethrin 0.3, 1, and 3 mg/kg/day (females and 
males) were stored in 10% formaldehyde solution for at least 7 days. After routine 
processing, 3-μm-thick paraffin sections were cut and stained with hematoxylin 
and eosin. Thyroid sections were subjectively evaluated for several parameters of 
thyroid activity including total area analyzed (μm2), total colloid area (μm2), col-
loid/total area (%), number of colloid, average colloid area (μm2), average colloid 
diameter (μm), total epithelial area (μm2), and epithelial/total area (%) [42] by 
Tissue Phenomics (Definiens AG, Munich, Germany).
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3. Statistical analysis
Data are expressed as the mean ± standard deviation (SD). Data for the mean ini-
tial or necropsy body weight, mean age, body weight upon VO or PPS, organ weight, 
and hormone levels were analyzed for homogeneity of variance by using Bartlett’s 
test. When samples were proven to be homogeneous, nonparametric analysis of vari-
ance was applied. Absolute organ weight was analyzed using analysis of covariance 
with body weight upon necropsy as a covariate. When a significant treatment effect 
was observed, Dunnett’s test (control vs. treatment groups) was used to compare the 
treatment groups. The level of statistical significance was set a priori at α = 0.05.
4. Results
4.1 Effects on body and organ weights
During the study period, no clinical signs of toxicity were detected in any treat-
ment group of male or female rats. EE significantly decreased the body weights of the 
female rats from PND 25 to 42 (Figure 1A). However, in contrast to the control group, 
deltamethrin did not change the body weight of the female or male rats (Figure 1B).
Figure 1. 
Body weight changes in Wistar female rats treated with 17α-ethinyl estradiol 5 mg/kg/day (EE5), testosterone 
propionate 0.4 mg/kg/day (TP 0.4), flutamide 3 mg/kg/day (Flu 3), and deltamethrin 0.3, 1, and 3 mg/kg/day 
(Delta 0.3, Delta 1, and Delta 3). Female rats were dosed daily starting at 21 days of age and this was continued 
until necropsy on day 42 (A), and male rats were dosed daily starting at 22 days of age and this was continued 
until necropsy on day 53 (B). EE significantly decreased the body weight during the treatment period. Data are 
expressed as mean ± SD of 10 animals per treatment group. *Significantly different from the vehicle control, 
P < 0.05.
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Treatments Vehicle 
control
EE1 (mg/kg/
day)
TP2 Flutamide Deltamethrin (mg/kg/day)
5 0.4 3 0.3 1 3
Female
Sample size 
(n)
10 10 10 10 10
Initial body 
weight (g)
59 ± 3 60 ± 4 59 ± 4 61 ± 4 60 ± 2
Final body 
weight (g)
173 ± 10 119 ± 7*** 173 ± 15 177 ± 6 177 ± 7
Final body 
weight (%)
100 69 100 102 102
Body weight 
gain (g)
114 ± 9 59 ± 6*** 114 ± 14 116 ± 7 117 ± 7
Male
Sample size 
(n)
10 10 10 10 10 10
Initial body 
weight (g)
69.6 ± 3.5 70 ± 3 69 ± 5 70 ± 3 71 ± 3 66 ± 4
Final body 
weight (g)
331 ± 18 328 ± 25 328 ± 25 328 ± 23 331 ± 14 308 ± 14**
Final body 
weight (%)
100 99 99 99 100 93
Body weight 
gain (g)
261 ± 16 260 ± 21 257 ± 21 258 ± 22 260 ± 12 242 ± 12
1EE: 17α-ethinyl estradiol;  2TP: testosterone propionate, p-value = *≤0.05, **≤0.01, ***≤0.005.
Table 1. 
General growth in the female and male rats.
Treatments Vehicle 
control
EE1 (mg/kg/
day)
Deltamethrin (mg/kg/day)
5 0.3 1 3
Sample size 
(n)
10 10 10 10 10
Liver (g) 8.2 ± 0.6 6.1 ± 0.4*** 8.0 ± 1.2 8.1 ± 0.7 8.1 ± 0.6
Kidney (g) 1.6 ± 0.2 1.2 ± 0.1*** 1.6 ± 1.2 1.6 ± 0.1 1.6 ± 0.1
Pituitary (mg) 10.2 ± 1.4 15.7 ± 6.4* 10.0 ± 1.3 10.7 ± 1.8 12.1 ± 3.3
Adrenals (mg) 55.8 ± 7.0 36.8 ± 4.8*** 50.9 ± 5.9 53.1 ± 5.2 52.3 ± 7.8
Ovaries (mg) 94.3 ± 14.5 59.4 ± 13.7*** 90.9 ± 17.1 92.7 ± 14.5 98.5 ± 23.7
Uterus, wet 
(mg)
427.5 ± 191.8 583.3 ± 328.8 383.6 ± 237.8 508.6 ± 2773.6 431.7 ± 221.5
Uterus, 
blotted (mg)
344.5 ± 71.8 364.6 ± 58.8 303.9 ± 93.5 357.4 ± 100.2 340.2 ± 86.6
Thyroid w/o 
trachea (mg)
138.3 ± 10.0 113.0 ± 12.1*** 130.5 ± 10.2 135.8 ± 8.7 140.5 ± 11.9
Thyroid w/o 
trachea (mg)
43.4 ± 7.8 38.3 ± 5.3 36.3 ± 6.4* 36.4 ± 6.6 42.5 ± 5.1
1EE: 17α-ethinyl estradiol; propionate, p-value = *≤0.05, **≤0.01, ***≤0.005.
Table 2. 
Organ weight at necropsy in the female rats.
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In the female rats, EE significantly decreased final body weight and weight gain 
in female rats, while deltamethrin did not. In the male rats, TP, flutamide, and delta-
methrin did not affect the body weight and weight gain except 3 mg/kg/day deltame-
thrin (Table 1). EE significantly changed the weights of the livers, kidneys, pituitary 
glands, adrenal glands, ovaries, and thyroid with trachea. For absolute organ weight 
treatment with 0.3 mg/kg/day, deltamethrin significantly reduced 16% of thyroid 
weight in the female rats, and the reduction was not dose-dependent (Table 2). For 
relative organ weight, EE significantly increased relative thyroid weight, while 0.3 
and 1 mg/kg/day deltamethrin significantly decreased it (Figure 2A) in female rats 
but not in male rats (Figure 2B).
In the male rats, TP significantly increased the absolute organ weights of the 
adrenals, seminal vesicles plus coagulating glands with and without fluid, left and 
right epididymides, and left and right testes. Flutamide significantly decreased 
the absolute organ weights of the seminal vesicles plus coagulating glands, LABC, 
epididymides, and penes. Treatment with 3 mg/kg/day deltamethrin significantly 
decreased the weights of the thyroids, livers, and penes in male rats. Although treat-
ment with 3 mg/kg/day deltamethrin significantly reduced 13% of penis weight in 
the male rats, the reduction was not dose-dependent (Table 3).
4.2 Effects on BUN, creatinine in serum
In order to investigate the effect of deltamethrin on blood chemistry, the blood 
urea nitrogen (BUN) and creatinine were selected as indicators. EE significantly 
increased BUN, while deltamethrin did not affect BUN and creatinine in female rats. 
TP and flutamide did affect the BUN and creatinine, while deltamethrin decreased 
marginally serum BUN in male rats (Table 4).
Figure 2. 
Relative thyroid weight in Wistar female (A) and male (B) rats treated with 17α-ethinyl estradiol 5 mg/kg/day 
(EE5), testosterone propionate 0.4 mg/kg/day (TP 0.4), flutamide 3 mg/kg/day (Flu 3), and deltamethrin 0.3, 
1, and 3 mg/kg/day (Delta 0.3, Delta 1, and Delta 3). EE significantly increased relative thyroid weight, while 
deltamethrin in low and middle dose significantly decreased it. There is no significant difference of relative 
thyroid weight between control and positive, negative and deltamethrin treatments. Data are expressed as 
mean ± SD of 10 animals per treatment group. *Significantly different from the vehicle control, P < 0.05.
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Treatments Vehicle control TP1 Flutamide Deltamethrin
0.4 3 0.3 1 3
Sample size (n) 10 10 10 10 10 10
Liver (g) 15.7 ± 1.1 14.8 ± 1.4 15.2 ± 1.0 14.8 ± 1.4 15.2 ± 0.8 13.6 ± 0.8***
Kidney (g) 2.7 ± 0.2 2.6 ± 0.3 2.5 ± 0.2 2.6 ± 0.2 2.6 ± 0.2 2.5 ± 0.2
Pituitary (mg) 13.3 ± 1.1 13.4 ± 1.6 13.4 ± 2.3 12.9 ± 2.2 13.1 ± 1.1 12.2 ± 1.7
Adrenals (mg) 57.5 ± 4.8 67.8 ± 5.8*** 58.2 ± 7.0 56.9 ± 6.5 58.4 ± 6.0 55.5 ± 5.5
Seminal vesicle + coagulating gland, with fluid (mg) 859 ± 100 1050 ± 111*** 627 ± 120*** 956 ± 151 954 ± 124 852 ± 103
Seminal vesicle + coagulating gland, without fluid (mg) 540 ± 46 675 ± 109** 447 ± 67** 574 ± 68 599 ± 85 571 ± 77
Prostate (mg) 233 ± 47 255 ± 53 210 ± 57 246 ± 26 233 ± 37 218 ± 45
LABC2 (mg) 732 ± 109 779 ± 99 585 ± 97** 733 ± 94 716 ± 82 648 ± 75
Left epididymis (mg) 229 ± 14 199 ± 10*** 196 ± 24** 241 ± 20 236 ± 28 224 ± 16
Right epididymis (mg) 235 ± 21 197 ± 10*** 196 ± 24** 247 ± 21 234 ± 28 217 ± 18
Left testis (mg) 1409 ± 75 1013 ± 209*** 1415 ± 118 1410 ± 115 1380 ± 105 1394 ± 116
Right testis (mg) 1407 ± 59 1018 ± 218*** 1432 ± 139 1388 ± 110 1409 ± 99 1390 ± 134
Thyroid with trachea (mg) 183.4 ± 23.8 188.8 ± 18.2 182.1 ± 12.4 190.3 ± 15.7 191.7 ± 12.4 175.1 ± 11.4
Thyroid without trachea (mg) 47.0 ± 7.7 49.1 ± 5.6 45.7 ± 5.8 48.5 ± 5.3 46.9 ± 6.3 40.6 ± 3.7*
Penis (mg) 253 ± 24 268 ± 19 228 ± 26* 256 ± 24 252 ± 17 234 ± 16*
1TP: testosterone propionate, 2LABC: levator ani plus bulbocarvernosus muscles, p-value = *≤0.05, **≤0.01, ***≤0.005.
Table 3. 
Organ weight at necropsy in the male rats.
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Treatments Vehicle control EE1 (mg/kg/day) TP2 (mg/kg/day) Flutamide (mg/kg/day) Deltamethrin (mg/kg/day)
5 0.4 3 0.3 1 3
Female
Sample size (n) 10 10 10 10 10
BUN3 (mg/dL) 19.1 ± 4.0 24.2 ± 3.4** 18.0 ± 2.0 17.0 ± 4.7 16.8 ± 4.4
Creatinine (mg/dL) 0.27 ± 0.05 0.24 ± 0.05 0.26 ± 0.05 0.23 ± 0.05 0.25 ± 0.05
Male
Sample size (n) 10 10 10 10 10 10
BUN (mg/dL) 19.1 ± 2.2 19.2 ± 2.2 18.1 ± 1.9 17.5 ± 2.0 16.8 ± 2.2* 16.2 ± 2.2*
Creatinine (mg/dL) 0.29 ± 0.03 0.27 ± 0.08 0.28 ± 0.04 0.28 ± 0.04 0.3 ± 0.00 0.26 ± 0.05
1EE: 17α-ethinyl estradiol; 2TP: testosterone propionate; 3BUN: blood urea nitrogen; p-value = *≤0.05 , **≤0.01.
Table 4. 
BUN, creatine in the female and male rats.
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4.3 Effects on VO and estrous cyclicity in female rats
The mean age and body weight upon VO were 27.9 days and 95.5 g, respectively, 
in the control female rats. Treatment with EE significantly advanced VO to 25.4 days 
of age and substantially reduced the mean body weight at the time of VO to 70.7 g. 
VO in EE-treated rats was first detected at 24 days of age in most rats. Treatment with 
3 mg/kg/day deltamethrin significantly delayed the mean time of VO (32.3 days) and 
increased the mean body weight to 127.3 g at the time of VO (Figure 3A).
The estrous cycles of individual animals were evaluated from the day after VO 
until the end of the study. Most control rats exhibited regular cycling, although three 
Figure 3. 
Mean age and body weight at vaginal opening (VO) in Wistar female (A) and male (B) rats treated with 
17α-ethinyl estradiol 5 mg/kg/day (EE5) testosterone propionate 0.4 mg/kg/day (TP 0.4), flutamide 3 mg/kg/
day (Flu 3), and deltamethrin 0.3, 1, and 3 mg/kg/day (Delta 0.3, Delta 1, and Delta 3). Animals were dosed 
daily starting at 21 days of age and examined from the time and body weight of vaginal opening for 21 days 
for female rats. Animals were dosed daily starting at 22 days of age and examined from the time and body 
weight of preputial separation (PPS) for 31 days for male rats. *Significantly different from the vehicle control, 
P < 0.05.
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Treatments Vehicle control EE1 (mg/kg/day) TP2 (mg/kg/
day)
Flutmaide 
(mg/kg/day)
Deltamethrin (mg/kg/day)
5 0.4 3 0.3 1 3
Female
Sample size (n) 10 10 10 10 10
Total area analyzed (μm2) (×106) 2.4 ± 1.1 3.6 ± 0.9 2.2 ± 0.2 2.7 ± 1.7 3.2 ± 0.6
Total colloid area (μm2) (×106) 1.1 ± 0.5 1.9 ± 0.5 1.2 ± 0.2 1.2 ± 0.6 1.6 ± 0.3
Colloid/total area (%) 0.46 ± 0.04 0.51 ± 0.01 0.53 ± 0.05 0.48 ± 0.10 0.51 ± 0.06
Number of colloid 437 ± 206 869 ± 265 409 ± 16 479 ± 291 656 ± 157
Average colloid area (μm2) (×103) 2.6 ± 0.2 2.2 ± 0.1 2.8 ± 0.6 2.7 ± 0.6 2.6 ± 0.9
Average colloid diameter (μm) 57.2 ± 2.3 52.5 ± 1.3 59.8 ± 6.4 58.1 ± 6.3 56.9 ± 10.3
Total epithelial area (μm2) (×106) 1.2 ± 0.5 1.7 ± 0.3 0.9 ± 0.2 1.3 ± 0.9 1.5 ± 0.3
Epithelial/total area (%) 0.48 ± 0.06 0.46 ± 0.01 0.43 ± 0.07 0.47 ± 0.09 0.48 ± 0.06
Male
Sample size (n) 10 10 10 10 10 10
Total area analyzed (μm2) (×106) 4.0 ± 1.2 3.0 ± 0.7 2.8 ± 1.2 2.9 ± 0.9 3.4 ± 0.3 3.6 ± 0.4
Total colloid area (μm2) (×106) 1.7 ± 0.4 1.6 ± 0.4 1.2 ± 0.5 1.4 ± 0.3 1.6 ± 0.03 1.7 ± 0.4
Colloid/total area (%) 0.44 ± 0.08 0.51 ± 0.05 0.46 ± 0.14 0.56 ± 0.07 0.47 ± 0.03 0.46 ± 0.07
Number of colloid 619 ± 304 347 ± 133 435 ± 261 515 ± 304 669 ± 80 711 ± 152
Average colloid area (μm2) (×103) 2.8 ± 0.8 4.7 ± 0.8* 3.7 ± 2.6 3.2 ± 1.1 2.4 ± 0.3 2.4 ± 0.5
Average colloid diameter (μm) 59.9 ± 9.3 76.9 ± 6.8* 66.3 ± 23.2 62.7 ± 11.7 54.8 ± 3.0 55.0 ± 5.1
Total epithelial area (μm2) (×106) 2.1 ± 1.0 1.4 ± 0.4 1.5 ± 0.8 1.4 ± 0.7 1.8 ± 0.3 1.8 ± 0.1
Epithelial/total area (%) 0.53 ± 0.07 0.46 ± 0.04 0.56 ± 0.13 0.48 ± 0.06 0.52 ± 0.05 0.51 ± 0.04
1EE: 17α-ethinyl estradiol; 2TP: testosterone propionate, p-value = *≤0.05.
Table 5. 
Measurements of several parameters of thyroid activity in treatment with deltamethrin.
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rats exhibited diestrus for ≥4 days. VO occurred from PND 26 to 31. EE induced a 
lasting estrus in most rats and VO occurred from PND 24 to 26. Most rats treated 
with a low dosage (0.3 mg/kg/day) of deltamethrin had regular estrus and experi-
enced VO from PND 26 to 32. One rat exhibited no VO. Treatment with a medium-
strength dosage (1 mg/kg/day) of deltamethrin caused irregular cycling in four rats 
and delays in VO (PND 42) in one rat. Treatment with a high dosage (3 mg/kg/day) 
of deltamethrin prevented VO in two rats, irregular cycling in one rat, and a delay in 
VO between PND 30 and 36 in eight rats (data not shown).
4.4 Effects on PPS in male rats
The mean age and body weight of the male control rats upon PPS were 34.8 days 
and 173.5 g, respectively. TP substantially advanced the mean age of PPS to 30.8 days 
Figure 4. 
Measurements of serum 17β-estradiol (E2) treated with control, 17α-ethinyl estradiol 5 mg/kg/day (EE5) 
testosterone propionate 0.4 mg/kg/day (TP 0.4), flutamide 3 mg/kg/day (Flu 3), and deltamethrin 0.3, 1, and 
3 mg/kg/day (Delta 0.3, Delta 1, and Delta 3) in rats. EE significantly increased serum E2 concentration, while 
deltamethrin decreased it in female rats (A). Deltamethrin significantly increased E2 in low dose but decreased 
it in middle dose in male rats (B).
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and reduced the mean body weight at the time of PPS to 138.9 g. However, neither del-
tamethrin nor flutamide affected the time or body weight at PPS, except for a reduc-
tion of body weight to 145 g induced by 3 mg/kg/day of deltamethrin (Figure 3B).
4.5 Effects on histology and several parameters of thyroid activity
The tissues of the thyroid glands in females and males, and the other tissues 
including pituitary glands (females and males), uteri, ovaries, testes, epididymides, 
and prostates (data not shown) of rats treated with control, EE, TP, flutamide, and 
deltamethrin were examined histologically. Histology of all tissues was comparable 
to that of the control group. No significant differences between the pituitary glands, 
uteri, ovaries, testes, epididymides, and prostates were detected between the 
controlled and treated male and female rats. Because 0.3 mg/kg/day deltamethrin 
Figure 5. 
Measurements of serum thyroxine (T4) treated with control, 17α-ethinyl estradiol 5 mg/kg/day (EE5) 
testosterone propionate 0.4 mg/kg/day (TP 0.4), flutamide 3 mg/kg/day (Flu 3), and deltamethrin 0.3, 1, 
and 3 mg/kg/day (Delta 0.3, Delta 1, and Delta 3) in rats. Deltamethrin significantly decreased serum T4 
concentrations (A). No obvious effect was observed in male rats (B).
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significantly reduced absolute thyroid weight (Table 2) and 0.3 and 1 mg/kg/day 
deltamethrin significantly decreased the relative thyroid weight (Figure 2A) in 
female rats, we measured the several parameters of thyroid activity. EE, TP, flu-
tamide, and deltamethrin did not affect total area analyzed (μm2), total colloid area 
(μm2), colloid/total area (%), number of colloid, average colloid area (μm2), aver-
age colloid diameter (μm), total epithelial area (μm2), and epithelial/total area (%) 
except TP increasing average colloid area and average colloid diameter (Table 5).
4.6 Effects on serum hormone concentrations in female and male rats
For the female rats, EE significantly decreased serum luteinizing hormone 
(LH) and testosterone but increased 17ß-estradiol (E2) (Figure 4A) and TSH 
(Figure 7A) serum concentrations, and there is no effect on aromatase (data now 
Figure 6. 
Measurements of serum triiodothyronine (T3) treated with control, 17α-ethinyl estradiol 5 mg/kg/day (EE5) 
testosterone propionate 0.4 mg/kg/day (TP 0.4), flutamide 3 mg/kg/day (Flu 3), and deltamethrin 0.3, 1, and 
3 mg/kg/day (Delta 0.3, Delta 1, and Delta 3) in rats. Deltamethrin significantly decreased T3 concentrations 
in female rats (A), while low and high dose significantly increased in male rats (B).
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shown), follicular-stimulating hormone (FSH) (data now shown), thyroxine 
(T4) (Figure 5A), and triiodothyronine (T3) (Figure 6A). Deltamethrin tended 
to decrease the serum aromatase concentration and did significantly in 1 mg/kg/
day (data now shown). Deltamethrin showed no effect on serum concentrations 
of LH, FSH, and testosterone (data now shown). Deltamethrin significantly 
increased 17β-estradiol (E2) with dose-dependent manner (Figure 4A). Also, 
deltamethrin significantly decreased serum concentrations of T4 (Figure 5A), T3 
(Figure 6A), and TSH (Figure 7A).
For the male rats, TP significantly decreased serum concentrations of LH and FSH, 
and there were no effect on aromatase, E2, T, T4, T3, and TSH. Flutamide significantly 
increased serum T, while there were no effect on aromatase (data now shown), LH 
(data now shown), FSH (data now shown), E2 (Figure 4B), T4 (Figure 5B), T3 
(Figure 6B), and TSH (Figure 7B).
For the female rats, EE significantly increased 89% of TSH. However, deltamethrin 
significantly decreased 60–64% of T3, 70–80% of T4, and 51–55% of TSH concentra-
tions. By contrast, for the male rats, 0.3 and 3 mg/kg/day of deltamethrin significantly 
Figure 7. 
Measurements of serum thyroid-stimulating hormone (TSH) treated with control, 17α-ethinyl estradiol 
5 mg/kg/day (EE5) testosterone propionate 0.4 mg/kg/day (TP 0.4), flutamide 3 mg/kg/day (Flu 3), and 
deltamethrin 0.3, 1, and 3 mg/kg/day (Delta 0.3, Delta 1, and Delta 3) in rats. EE significantly increased TSH 
concentration, while deltamethrin significantly decreased it in female rats (A). In contrary to female rats, 
deltamethrin increased TSH concentrations in male rats (B).
Comparative Endocrinology of Animals
18
increased 14 and 36% of T3 concentrations, and 0.3, 1, and 3 mg/kg/day deltamethrin 
significantly increased 100, 130, and 96% of TSH concentrations (Table 3).
5. Discussion
This study investigated whether deltamethrin alters pubertal development and 
thyroid function on the basis of previous reports regarding testicular and epididy-
mal toxicity, neurotoxicity in juvenile/peripubertal rats, and TR antagonism in 
Tox21 HTS assays. Furthermore, the study was aimed at verifying whether Tox21 
reporter activity data can predict the endocrine-disrupting activity of deltamethrin. 
Deltamethrin was observed to delay age and increase body weight at VO, accom-
panied with decreased T3, T4, and TSH concentrations in female rats. Based on the 
reductions of T3, T4, and TSH concentrations, delay in VO age, and induction of an 
irregular estrous cycle, we propose that deltamethrin disrupts the HPT and hypotha-
lamic-pituitary-ovarian (HPO) axes in female rats. By contrast, deltamethrin failed 
to delay the age of PPS and increased T3 and TSH concentrations in the male rats. 
Because deltamethrin reduced T3, T4, and TSH levels in a sex-dependent manner 
and correlated with disturbances in pubertal development, the delay in female 
pubertal development might be a consequence of thyroid disruption.
The HPO axis has been demonstrated by Ortega et al. [43, 44]. Disruption of 
thyroid function with 133-iodine in adult female rats resulted in irregular cycles, 
atrophied and underweight ovaries, and decreased serum T3 and T4. However, T3 
replacement restored normal cycles and ovary weights [43]. Similarly, T4 replace-
ment restored estrous cycles and pubertal patterns of gonadotropin secretion in 
hypothyroid female rats [44]. Jiang et al. [45] also reported that T4 treatment 
improved follicular development rather than gonadotropin secretion in infertile 
immature hypothyroid rdw rats. By contrast, Tamura [46] reported that hypothy-
roidism increases ovarian hormonal secretion and folliculogenesis during equine 
chorionic gonadotropin-induced follicle development in immature female rats. Thus, 
the involvement of the HPG ovary in hypothyroidism-induced disruption of female 
puberty development is still unclear. In the present study, the FSH and LH levels of 
deltamethrin did not change (data not shown), suggesting that the HPG ovary might 
not be involved in the mechanism for the delay of female puberty by deltamethrin.
The results of the present study show that deltamethrin decreased concentrations 
of T3, T4, and TSH in female rat serums. Because the morphology of the thyroid glands 
was normal after deltamethrin treatment, it is unlikely that deltamethrin disturbed the 
biosynthesis function of TH in the thyroid glands. Given that TSH positively regulates 
the biosynthesis of TH, the decreases in T3 and T4 levels might be consequences of the 
decrease in TSH by deltamethrin. TSH is released from the anterior pituitary, which 
also releases LH and FSH. Because LH and FSH levels were not affected by deltame-
thrin, it is likely that the anterior pituitary function remained normal after deltame-
thrin treatment. Therefore, it is plausible that deltamethrin disturbed the regulatory 
mechanism for TSH synthesis or release through the anterior pituitary.
TSH is produced in pituitary thyrotrophs. It activates thyroid follicular cells 
and promotes thyroid cell proliferation and TH synthesis [47, 48]. TSH synthesis is 
largely dependent on serum TH levels. Patients with primary hyperthyroidism or 
primary hypothyroidism consistently demonstrate suppressed or increased serum 
TSH levels, respectively [49]. On the basis of the results of the present study, we infer 
that deltamethrin might damage TSH production or release, subsequently resulting 
in reductions of T3 and T4 in female rats. Furthermore, the reduction in TSH level 
caused by deltamethrin was sex-dependent. A possible explanation for the difference 
might be responsiveness to the thyrotropin-releasing hormone. The presence of a 
19
Deltamethrin Alters Thyroid Hormones and Delays Pubertal Development in Male and Female…
DOI: http://dx.doi.org/10.5772/intechopen.81107
sex difference in HPT function was suggested by McClain et al. [50]. Phenobarbital 
increased TSH secretion as a compensatory response to the increased T4 metabolism 
and excretion. Higher TSH responsiveness to TRH has been observed in male rats but 
not in female rats, and this difference was attributed to testosterone [51]. Therefore, 
a possible explanation for the difference in responses to deltamethrin between male 
and female rats might be that male rats are more susceptible to deltamethrin than 
female rats are in terms of TSH response.
In contrast to the negative regulation of TSH production by THs, TSH produc-
tion is positively regulated by TRH. Mice devoid of the TRH gene were shown to 
exhibit hypothyroidism accompanied by low circulating TSH levels and reduced 
numbers of TSH immunopositive cells in their pituitary glands [52]. In TRH and TR 
β-subunit double knockout mice, basal serum TSH levels were shown to be low and 
hypothyroidism failed to increase serum TSH concentrations [53]. These studies 
have demonstrated the pivotal role of TRH in the regulation of TSH production. The 
reduction of TSH in female rats might be regulated by TRH.
TSH secretion is increased by hypothyroidism [49]. In the present study, because 
deltamethrin increased the TSH levels in the male rats, it is possible that deltamethrin 
moderately reduced TH levels, which were overcome by the normal TSH regulatory 
system in the male rats. However, the reduction in TH levels could not activate the posi-
tive regulatory mechanism for TSH secretion in the female rats, and TH levels remained 
low. These results are strongly correlated with sex-dependent delay in pubertal develop-
ment. A more detailed study must be conducted to elucidate the mechanisms.
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